Epitalon vs Cagrilintide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Epitalon
Epitalon (Epithalon) is a synthetic tetrapeptide based on the natural peptide epithalamin, produced by the pineal gland. It is primarily studied for its effects on telomerase activation.
Full details →Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Side-by-Side Comparison
| Aspect | Epitalon | Cagrilintide |
|---|---|---|
| Mechanism | Stimulates telomerase production, which can lengthen telomeres on DNA strands. May also regulate melatonin production and circadian rhythms. | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. |
| Typical Dosage | Typical protocols: 5-10mg daily for 10-20 days, repeated 2-3 times per year. | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. |
| Administration | Subcutaneous or intramuscular injection. Usually administered in cycles rather than continuously. | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. |
| Side Effects | Generally well-tolerated. May affect sleep patterns initially. | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. |
| Best For |